Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Tango Therapeutics, Inc. (TNGX) had Stock-Based Compensation of $20.45M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$53.81M |
|
$15.88M |
|
-- |
|
$53.81M |
|
$39.74M |
|
$14.07M |
|
$1.80M |
|
$15.87M |
|
$15.87M |
|
$15.88M |
|
$15.88M |
|
$15.88M |
|
$15.88M |
|
$14.07M |
|
$14.07M |
|
110.97M |
|
117.78M |
|
$0.14 |
|
$0.13 |
|
| Balance Sheet Financials | |
$163.78M |
|
$7.35M |
|
$46.36M |
|
$210.14M |
|
$18.44M |
|
-- |
|
$31.66M |
|
$50.10M |
|
$160.03M |
|
$160.03M |
|
$160.03M |
|
111.57M |
|
| Cash Flow Statement Financials | |
$-109.17M |
|
$94.85M |
|
$3.12M |
|
$72.10M |
|
$60.91M |
|
$-11.19M |
|
|
Stock-Based Compensation |
$20.45M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.88 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
26.15% |
|
26.15% |
|
-- |
|
29.50% |
|
29.52% |
|
$-109.99M |
|
-- |
|
-- |
|
-- |
|
0.26 |
|
-- |
|
-- |
|
-- |
|
9.93% |
|
9.93% |
|
7.56% |
|
9.93% |
|
$1.43 |
|
$-0.93 |
|
$-0.93 |
|